Aquestive Therapeutics, Inc.
AQSTReported to SECin USCIK 0001398733Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 8. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Barber DanielPresident and CEO | Open-market sell | $120,48825,000 shares | Sep 16, 2026 | Barber DanielPresident and CEO | $120,488 | Open-market sell | 25,000 | Sep 16, 2026 |
| Korczynski SherryChief Commercial Officer | Option exercise | nothing paid8,750 shares | Sep 11, 2026 | Korczynski SherryChief Commercial Officer | nothing paid | Option exercise | 8,750 | Sep 11, 2026 |
| Korczynski SherryChief Commercial Officer | Open-market sell | $45,6758,750 shares | Sep 11, 2026 | Korczynski SherryChief Commercial Officer | $45,675 | Open-market sell | 8,750 | Sep 11, 2026 |
| Korczynski SherryChief Commercial Officer | Option exercise | $23,1888,750 shares | Sep 11, 2026 | Korczynski SherryChief Commercial Officer | $23,188 | Option exercise | 8,750 | Sep 11, 2026 |
| Barber DanielPresident and CEO | Open-market sell | $107,16825,000 shares | Aug 18, 2026 | Barber DanielPresident and CEO | $107,168 | Open-market sell | 25,000 | Aug 18, 2026 |
Lobbying
From the quarterly LD-2 filings at the U.S. Senate — a different register, and a different kind of fact.
This is not a trade and it is not scored. A lobbying filing says who lobbied for whom, on which issues, and for how much — it says nothing about the share price and nothing about this company’s insiders. The link between the client names in that register and Aquestive Therapeutics, Inc. is a reviewed rule of ours: an LD-2 names a client and carries no ticker, no CIK and no LEI.
Lobbying reported per quarter
reported amounts per quarter, latest version of each report
Reported income: what lobbying firms reported receiving from this company's clients, per quarter.